Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529

Expert Rev Vaccines. 2003 Apr;2(2):219-29. doi: 10.1586/14760584.2.2.219.

Abstract

MPL (Corixa) adjuvant is a chemically modified derivative of lipopolysaccharide that displays greatly reduced toxicity while maintaining most of the immunostimulatory activity of lipopolysaccharide. MPL adjuvant has been used extensively in clinical trials as a component in prophylactic and therapeutic vaccines targeting infectious disease, cancer and allergies. With over 33,000 doses administered to date, MPL adjuvant has emerged as a safe and effective vaccine adjuvant. Recently, scientists at Corixa Corporation have developed a library of synthetic lipid A mimetics (aminoalkyl glucosaminide 4-phosphates) with demonstrated immunostimulatory properties. Similar to MPL adjuvant, these synthetic compounds signal through Toll-like receptor 4 to stimulate the innate immune system. One of these compounds, Ribi.529 (RC-529), has emerged as a leading adjuvant with a similar efficacy and safety profile to MPL adjuvant in both preclinical and clinical studies.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Antigens
  • Cancer Vaccines / administration & dosage
  • Cell Wall Skeleton / administration & dosage*
  • Clinical Trials as Topic
  • Cord Factors / administration & dosage*
  • Hepatitis B Vaccines / administration & dosage
  • Herpes Simplex Virus Vaccines / administration & dosage
  • Humans
  • Hypersensitivity / therapy
  • Ligands
  • Lipid A / administration & dosage*
  • Lipid A / analogs & derivatives*
  • Malaria Vaccines / administration & dosage
  • Membrane Glycoproteins / metabolism
  • Pneumococcal Vaccines / administration & dosage
  • Receptors, Cell Surface / metabolism
  • Safety
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • Vaccines / administration & dosage*

Substances

  • Adjuvants, Immunologic
  • Antigens
  • Cancer Vaccines
  • Cell Wall Skeleton
  • Cord Factors
  • Hepatitis B Vaccines
  • Herpes Simplex Virus Vaccines
  • Ligands
  • Lipid A
  • Malaria Vaccines
  • Membrane Glycoproteins
  • Pneumococcal Vaccines
  • Receptors, Cell Surface
  • Ribi adjuvant
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • Vaccines
  • monophosphoryl lipid A